We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases.
Zerlasiran (SLN360)
Cardiovascular Disease due to high Lp(a)
Lp(a)
SLN124
Thalassemia
Polycythemia Vera (PV)
TMPRSS6
Multiple programs
Undisclosed
Undisclosed
SLN-HAN-1
Undisclosed
Undisclosed
*
SLN501
SLN-MNK-2
SLN-MNK-3
Complement-mediated diseases
C3
2nd complement target
3rd complement target
SLN-AZ-1
SLN-AZ-2
cardiovascular, renal, metabolic and respiratory diseases
Undisclosed
Undisclosed
* Silence retains exclusive rights to this program outside of the China region, including Hong Kong, Macau and Taiwan